Abstract:
Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
Abstract:
The present invention relates to the assessment of lung cancer. It discloses the use of protein AP endonuclease (APEX) in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample derived from an individual by measuring APEX in the sample. Measurement of APEX can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
Abstract:
The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
Abstract:
The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
Abstract:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein proteasome subunit alpha 3 (PSA3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSA3 in said sample. Measurement of PSA3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Abstract:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RS15A (ribosomal protein S15a) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RS15A in said sample. Measurement of RS15A can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Abstract:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein CBP2 (collagen-binding protein 2) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring CBP2 in said sample. Measurement of CBP2 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Abstract:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Abstract:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein SPEE (sperrnidine synthase) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring SPEE in said sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Abstract:
The ore which contains gold and at least one of the metals silver, copper, nickel, zinc or iron is calcined at temperatures in the range from 500.degree. to 900.degree. C. with the addition of oxygen-containing gas, thereby producing a metal-oxide-containing solids mixture and a SO.sub.2 -containing exhaust gas. The SO.sub.2 containing exhaust gas is brought in contact with aqueous solution, thereby producing a sulfite-containing solution. The solids mixture from the calcination is cooled to temperatures in the range from 50.degree. to 300.degree. C. and is stirred up with the sulfite-containing solution. Metal oxides are dissolved, and a sulfate-containing solution os formed. In a first separating zone, the sulfate-containing solution is separated from the solids, and either the solids are supplied to a gold leaching or the sulfate-containing solution is subjected to a further treatment for the separation of nonferrous metals.